[Articles] Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Nivolumab alone does not warrant further study in an unselected sarcoma population given the limited efficacy. Nivolumab combined with ipilimumab demonstrated promising efficacy in certain sarcoma subtypes, with a manageable safety profile comparable to current available treatment options. The combination therapy met its predefined primary study endpoint; further evaluation of nivolumab plus ipilimumab in a randomised study is warranted.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Sandra P D'Angelo, Michelle R Mahoney, Brian A Van Tine, James Atkins, Mohammed M Milhem, Balkrishna N Jahagirdar, Cristina R Antonescu, Elise Horvath, William D Tap, Gary K Schwartz, Howard Streicher Tags: Articles Source Type: research